Literature DB >> 2405396

Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA.

A W Cochrane1, C H Chen, C A Rosen.   

Abstract

A region of potential complex secondary structure within the human immunodeficiency virus env mRNA has been implicated in Rev-mediated export of viral structural mRNAs from the nucleus to the cytoplasm. By using an RNase protection gel-mobility-shift assay, we demonstrate that purified Rev protein forms a stable complex with this Rev-responsive RNA. RNAs with mutations designed to disrupt formation of a predicted stem structure no longer interact with Rev. However, Rev binding is restored upon annealing of the two complementary RNAs that make up the stem. These results suggest that direct interaction of Rev with the Rev-responsive element could facilitate transport of human immunodeficiency virus structural mRNAs from the nucleus to the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405396      PMCID: PMC53438          DOI: 10.1073/pnas.87.3.1198

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Structural and functional characterization of the human immunodeficiency virus rev protein.

Authors:  A Perkins; A W Cochrane; S M Ruben; C A Rosen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

2.  Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function.

Authors:  M H Malim; S Böhnlein; J Hauber; B R Cullen
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

3.  The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization.

Authors:  M Emerman; R Vazeux; K Peden
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

4.  The art gene product of human immunodeficiency virus is required for replication.

Authors:  E Terwilliger; R Burghoff; R Sia; J Sodroski; W Haseltine; C Rosen
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Structure of simian immunodeficiency virus regulatory genes.

Authors:  S Colombini; S K Arya; M S Reitz; L Jagodzinski; B Beaver; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

8.  The human immunodeficiency virus rev protein is a nuclear phosphoprotein.

Authors:  A Cochrane; R Kramer; S Ruben; J Levine; C A Rosen
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

9.  Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species.

Authors:  M H Malim; S Böhnlein; R Fenrick; S Y Le; J V Maizel; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins.

Authors:  M Hidaka; J Inoue; M Yoshida; M Seiki
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

View more
  75 in total

1.  Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.

Authors:  D McDonald; T J Hope; T G Parslow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element.

Authors:  H P Bogerd; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

Authors:  T J Hope; N P Klein; M E Elder; T G Parslow
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1.

Authors:  L Solomin; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure.

Authors:  S M Holland; N Ahmad; R K Maitra; P Wingfield; S Venkatesan
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Minimal Rev-response element for type 1 human immunodeficiency virus.

Authors:  X J Huang; T J Hope; B L Bond; D McDonald; K Grahl; T G Parslow
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate.

Authors:  K S Cook; G J Fisk; J Hauber; N Usman; T J Daly; J R Rusche
Journal:  Nucleic Acids Res       Date:  1991-04-11       Impact factor: 16.971

8.  Rev-dependent expression of human immunodeficiency virus type 1 gp160 in Drosophila melanogaster cells.

Authors:  M Ivey-Hoyle; M Rosenberg
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

9.  RU5 of Mason-Pfizer monkey virus 5' long terminal repeat enhances cytoplasmic expression of human immunodeficiency virus type 1 gag-pol and nonviral reporter RNA.

Authors:  Stacey Hull; Kathleen Boris-Lawrie
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.

Authors:  J Katahira; T Ishizaki; H Sakai; A Adachi; K Yamamoto; H Shida
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.